Federal Science and Technology Grants

This funding opportunity supports early-stage research aimed at improving understanding and treatment of rare autoimmune neuropathies affecting the peripheral nervous system, specifically targeting innovative approaches to disease mechanisms, biomarkers, and therapies.

This grant provides funding to state and local governments to conduct DNA testing and improve evidence preservation in violent felony cases, helping to address wrongful convictions and support justice.

This grant provides funding for researchers to conduct innovative studies on ovarian cancer, focusing on impactful solutions that benefit patients and their families.

This program provides funding to support collaborations between formal methods researchers and experts in various computer and engineering fields to improve system design and reliability through innovative methodologies and educational initiatives.

This funding opportunity seeks innovative research proposals from a variety of organizations, including universities and small businesses, to develop advanced biotechnological solutions that enhance U.S. national security and address global challenges.

The ARP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ASD. Applications are strongly encouraged to address one of the FY24 ARP Clinical Trial Award Areas of Interest. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Research funded by the FY24 ARP should be responsive to the needs of people with ASD, their families, and/or caregivers. Researchers are therefore encouraged to establish and utilize effective collaborations and partnerships with community members to maximize the impact potential of the proposed research.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.

Project Title: Integrated Training Area Management (ITAM) Support for Fort Hunter Liggett, CaliforniaA cooperative agreement is being offered ONLY to members of the Cooperative Ecosystem Studies Units (CESU) Program Region(s) identified above. Award will be made upon mutual agreement and acceptance of the terms and conditions contained in the request for proposal and the of the recipients CESU Master Agreement.Note the established CESU Program indirect rate is 17.5%.Responses to this Request for Statements of Interest will be used to identify potential organizations for this project. Approximately $509,141 is expected to be available to support this project for the base period. Additional funding may be available to the successful recipient for optional tasks and/or follow on work in subsequent years.NOTE: This project will be awarded under the authority of 16 USC 670c-1, Sikes Act. For projects for the implementation and enforcement of integrated natural resources management plans, priority shall be given to award to Federal and State agencies having responsibility for the conservation or management of fish or wildlife.Period of Performance. The Base will be 12 months from the date of award. There may be up to six 12-month follow-on periods based on availability of funding.Description of Anticipated Work: See attached Statement of ObjectivesNOTE: At this time we are only requesting that you demonstrate available qualifications and capability for performing similar or same type of work by submitting a Statement of Interest. A full proposal and budget are NOT requested at this time.Submission of Your Statement of Interest1. Statements of Interest are due by 12:00 P.M., Central Time, on 7 SEP 2024.2. Direct questions no later than 26 AUG 2024 to:Sandra Justman, Grants SpecialistUSACE, Fort Worth DistrictEmail: [email protected]: 817-886-1073Brian Hesford, Project ManagerUSACE, Fort Worth DistrictEmail: [email protected]: 402-200-8268Review of Statements Received: All statements of interest received from a member of the CESU Region(s) identified above will be evaluated by a board comprised of one or more people at the receiving installation or activity, who will determine whichstatement(s) best meet the program objectives: offer the most highly qualified Principal Investigator, have the most relevant experience and the highest capability to successfully meet the program objectives. Submitters whose statements aredetermined to best meet the program objectives will be invited to submit a full proposal.Please see Related Documents Tab for Full RSOI Information

The FY24 PCRP Exploration Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Submission Type, for more information. New for FY24: Clinical research is allowed. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities. Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 Exploration Hypothesis Development Award should not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $3.60M to fund approximately 15 Exploration Hypothesis Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. Research Involving Animals: All research funded by the FY24 PCRP Exploration-Hypothesis Development Award involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO; previously the Human Research Protection Office), Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions for additional information.

To obtain a copy of the Funding Opportunity Announcement (FOA) please go to the ARPA-E website at https://arpa-e-foa.energy.gov. To apply to this FOA, Applicants must register with and submit application materials through ARPA-E eXCHANGE (https://arpa-e-foa.energy.gov/Registration.aspx). For detailed guidance on using ARPA-E eXCHANGE, please refer to the ARPA-E eXCHANGE User Guide (https://arpa-e-foa.energy.gov/Manuals.aspx). ARPA-E will not review or consider concept papers submitted through other means. For problems with ARPA-E eXCHANGE, email [email protected] (with FOA name and number in the subject line). Questions about this FOA? Check the Frequently Asked Questions available at http://arpa-e.energy.gov/faq. For questions that have not already been answered, email [email protected]. The purpose of this modification is to incorporate changes to Funding Opportunity Announcement. Accordingly, this modification: Inserted new Exploratory Topic, Topic M: H2SENSE. See Table 1. Exploratory Topics, Appendix M, and Total Amounts to be awarded on Cover Page. Updated Language in Appendix L Section 5.

This funding opportunity is designed to support small businesses in developing innovative technologies to efficiently recover valuable energy-related materials from wastewater, helping to enhance energy security and reduce environmental impact.

Environmental Conservation and Compliance Support for the Air Force Civil Engineer CenterA cooperative agreement is being offered ONLY to members of the Cooperative Ecosystem Studies Units (CESU) Program Region(s) identified above. Award will be made upon mutual agreement and acceptance of the terms and conditions contained in the request for proposal and the of the recipient's CESU Master Agreement. Note the established CESU Program indirect rate is 17.5%.Responses to this Request for Statements of Interest will be used to identify potential organizations for this project. Approximately $3,640,000 is expected to be available to support this project for the base period (Task 1-5). More specifically, the following is expected budget per task:Approximately $835,000 is expected to be available to support Task 1 for the base period.Approximately $835,000 is expected to be available to support Task 2 for the base period.Approximately $835,000 is expected to be available to support Task 3 for the base period.Approximately $835,000 is expected to be available to support Task 4 for the base period.Approximately $300,000 is expected to be available to support Task 5 for the base period.Additional funding may be available to the successful recipient for follow on work insubsequent years.NOTE: This project will be awarded under the authority of 16 USC 670c-1, Sikes Act:For projects for the implementation and enforcement of integrated natural resources management plans, priority shall be given to award to Federal and State agencies having responsibility for the conservation or management of fish or wildlife.Period of Performance. The base period of agreement will extend 12 months from date of award. There may be up to six 12-month follow-on periods based on availability of funding.Description of Anticipated Work: See attached Statement of ObjectivesNOTE: At this time we are only requesting that you demonstrate available qualifications and capability for performing similar or same type of work by submitting a Statement of Interest. A full proposal and budget are NOT requested at this time.Submission of Your Statement of InterestStatements of Interest are due by 12:00 P.M., Central Time, on 16 Aug 2024.Submit your Statement of Interest via e-mail attachments or direct questions to:Sandy JustmanGrants SpecialistUSACE, Fort Worth DistrictEmail: [email protected] Office: 817-886-1073Chanley JenkinsProject ManagerUSACE, Fort Worth DistrictEmail: [email protected]: 918-671-9132Greg Bonnell Project Manager USACE, Fort Worth District Email: [email protected] Office: 918-951-0591 Review of Statements Received: All statements of interest received from a member of the CESU Region(s) identified above will be evaluated by a board comprised of one or more people at the receiving installation or activity, who will determine which statement(s) best meet the program objectives: offer the most highly qualified Principal Investigator, have the most relevant experience and the highest capability to successfully meet the program objectives. Submitters whose statements are determined to best meet the program objectives will be invited to submit a full proposal. For complete information click on the Related Documents Tab

This funding opportunity is designed to support a wide range of research and technology projects related to space and Earth sciences, encouraging proposals from various organizations, including government, private, and non-profit entities.

This funding opportunity provides financial support for public diplomacy projects that strengthen U.S.-Slovenian relations and enhance community safety, prosperity, and resilience through initiatives involving both American and Slovenian participants.

This funding opportunity provides financial support to organizations and institutions working to prevent the proliferation of chemical weapons by enhancing partner nations' capabilities in detection, response, and compliance with international norms.

This funding opportunity supports U.S. institutions conducting research on snow hydrology to enhance understanding and prediction of snowpack evolution and its impact on water resources through suborbital investigations and remote sensing data.

This funding opportunity provides financial support for collaborative geologic mapping projects aimed at identifying and assessing critical mineral resources across the United States, benefiting researchers, state agencies, and organizations involved in geology and natural resource management.

The purpose of the Assistive Technology (AT) Alternative Financing Program (AFP) is to support programs that provide for the purchase of AT, such as a low-interest loan fund, an interest buy-down program, a revolving loan fund, a loan guarantee, an or an insurance program, that results in the acquisition of AT devices and services. Applicants for the AT AFP grant awards are required to provide an assurance that, and information describing the manner in which, the AFP will expand and emphasize consumer choice and control. Applicants should incorporate credit-building activities in their programs, including financial education and information about other possible funding sources. Successful applicants must emphasize consumer choice and control and build programs that will provide financing for the full array of AT devices and services and ensure that all people with disabilities, regardless of type of disability or health condition, age, level of income, and residence, have access to the program.

This funding opportunity supports innovative research projects aimed at improving burn care for military personnel, particularly in combat situations, by addressing unique medical challenges and enhancing treatment methods.

This funding opportunity provides financial support to U.S. small businesses developing innovative technologies for faster and more cost-effective mineral resource evaluation, particularly for rare earth elements and critical minerals essential for clean energy and advanced technologies.

This funding opportunity provides financial support for higher education institutions to train researchers, particularly those from underrepresented groups, in advanced disability and rehabilitation research to improve health and function outcomes for individuals with disabilities.